PEN — Penumbra Inc

NYSE · Health Care · Health Care Equipment & Supplies · CIK 1321732 ·
Last close
$318.71
Market Cap
$12.54B
52W High
$338.98
52W Low
$317.53
ADV30
432,507
Next earnings
2026-07-28
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 374,758,000 253,411,000 38,234,000 32,584,000 1,898,438,000 241,289,000 424,626,000
Dec 2025 385,385,000 262,128,000 59,233,000 47,343,000 1,826,519,000 186,897,000 398,916,000
Sep 2025 354,685,000 240,416,000 48,838,000 45,851,000 1,744,369,000 321,029,000 385,673,000
Jun 2025 339,455,000 224,010,000 40,828,000 45,270,000 1,674,809,000 421,768,000 380,858,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$276,664,000
Investing CF
$-434,721,000
Financing CF
$21,917,000
CapEx
$-63,933,000
Dividends Paid
Buybacks
$1,000
EPS Diluted TTM
$4.34
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$270,275,000
Inventory
$438,539,000
Receivables
$183,295,000
ST Investments
$374,371,000
EBIT TTM
$204,262,000
Pretax Income TTM
$202,955,000
Interest Exp TTM
$1,307,000
Analysts
14

Yahoo Snapshot (yfinance, live)

Total Revenue
$1,454,283,008
EBITDA
$203,963,008
Free Cash Flow
$141,799,872
Enterprise Value
$12,135,833,600
Total Cash
$615,660,032
Total Debt
$216,175,008
Shares Out
39,331,425
Trailing EPS
$4.33
Book Value
$37.48
ROE
12.7%
ROA
6.7%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 1,403,665,000 189,249,000 177,687,000 1,826,519,000 398,916,000 238,663,000
Dec 2024 1,194,615,000 86,224,000 14,012,000 1,533,181,000 382,250,000 168,481,000
Dec 2023 1,058,522,000 91,766,000 90,954,000 1,556,305,000 377,361,000 97,333,000
Dec 2022 847,133,000 6,082,000 -2,002,000 1,370,886,000 372,028,000 -55,661,000

TTM Snapshot

Revenues TTM
$975,780,000
NetIncome TTM
$45,320,000
OpCashFlow TTM
$0
Assets (Latest)
$1,533,181,000
Forward EPS
$6.29

Max Pain — expiry 2027-01-15

max pain strike: $380.00 · spot: $317.67 · call oi: 1,567 · put oi: 3,622
Expected Move to 2027-01-15: ±$124.00 (39.03%) — implied range $193.67$441.67 · ATM straddle on $320.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
ALGN ALIGN TECHNOLOGY INC $12.52B $174.84
SNNUF SMITH & NEPHEW PLC $12.79B $15.10
SNN SMITH & NEPHEW PLC $12.95B $30.57
SOLV Solventum Corp $13.66B $78.87
BAX BAXTER INTERNATIONAL INC $10.77B $20.86

News headlines (Yahoo Finance, 1h cache)

Penumbra Expands CAVT for Stroke to Europe with CE Mark for THUNDERBOLT
2026-06-15 13:00 · Yahoo
Boston Scientific Eyes Neurovascular Growth With Penumbra Thunderbolt Clearance
2026-06-13 07:17 · Yahoo
FDA clears Penumbra’s Thunderbolt thrombectomy platform for stroke
2026-06-12 15:34 · Yahoo
Penumbra's Thunderbolt Device Offers Revenue Upside Not Reflected in Estimates, RBC Says
2026-06-12 14:52 · Yahoo
Penumbra’s FDA nod for clot removal tech a win for Boston Scientific
2026-06-12 11:22 · Yahoo
Penumbra's THUNDERBOLT Receives FDA Clearance - Bringing Computer Assisted Vacuum Thrombectomy Technology to Stroke
2026-06-11 20:05 · Yahoo
GMED or PEN: Which Is the Better Value Stock Right Now?
2026-06-05 15:40 · Yahoo
Why Is Penumbra (PEN) Down 1.2% Since Last Earnings Report?
2026-06-05 15:30 · Yahoo
Here’s What Supports Penumbra’s (PEN) Revenue Growth and Margin Expansion
2026-06-05 13:14 · Yahoo
Boston Scientific Bets on Growth Through Strategic M&A Deals
2026-05-18 18:15 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.